Current status of drug screening and disease modelling in human pluripotent stem cells
Open Access
- 8 August 2012
- Vol. 35 (3), 281-298
- https://doi.org/10.1002/bies.201200053
Abstract
The emphasis in human pluripotent stem cell (hPSC) technologies has shifted from cell therapy to in vitro disease modelling and drug screening. This review examines why this shift has occurred, and how current technological limitations might be overcome to fully realise the potential of hPSCs. Details are provided for all disease-specific human induced pluripotent stem cell lines spanning a dozen dysfunctional organ systems. Phenotype and pharmacology have been examined in only 17 of 63 lines, primarily those that model neurological and cardiac conditions. Drug screening is most advanced in hPSC-cardiomyocytes. Responses for almost 60 agents include examples of how careful tests in hPSC-cardiomyocytes have improved on existing in vitro assays, and how these cells have been integrated into high throughput imaging and electrophysiology industrial platforms. Such successes will provide an incentive to overcome bottlenecks in hPSC technology such as improving cell maturity and industrial scalability whilst reducing cost.Keywords
This publication has 163 references indexed in Scilit:
- Disease‐specific phenotypes in dopamine neurons from human iPS‐based models of genetic and sporadic Parkinson's diseaseEMBO Molecular Medicine, 2012
- Dantrolene rescues arrhythmogenic RYR2 defect in a patient‐specific stem cell model of catecholaminergic polymorphic ventricular tachycardiaEMBO Molecular Medicine, 2012
- Production of De Novo Cardiomyocytes: Human Pluripotent Stem Cell Differentiation and Direct ReprogrammingCell Stem Cell, 2012
- In Situ Genetic Correction of the Sickle Cell Anemia Mutation in Human Induced Pluripotent Stem Cells Using Engineered Zinc Finger NucleasesThe International Journal of Cell Cloning, 2011
- A Model for Neural Development and Treatment of Rett Syndrome Using Human Induced Pluripotent Stem CellsCell, 2010
- High content screening: seeing is believingTrends in Biotechnology, 2010
- Parkinson's Disease Patient-Derived Induced Pluripotent Stem Cells Free of Viral Reprogramming FactorsCell, 2009
- Disease-Specific Induced Pluripotent Stem CellsCell, 2008
- High-Throughput Screening Assay for the Identification of Compounds Regulating Self-Renewal and Differentiation in Human Embryonic Stem CellsCell Stem Cell, 2008
- Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined FactorsCell, 2007